TY - JOUR
T1 - Donor lazaroid pretreatment improves viability of livers harvested from non-heart-beating rats
AU - Xu, Hua Sheng
AU - Stevenson, William C.
AU - Pruett, Timothy L.
AU - Jones, R. Scott
PY - 1996/1
Y1 - 1996/1
N2 - BACKGROUND: Lazaroids are potent inhibitors of lipid peroxidation. Whether the compounds can benefit the liver procured from non-heart-beating donors (NHBDs) is unknown. METHODS: Donor rats were pretreated with lazaroid U74006F (4.5 mg/kg) 1 hour before cardiac arrest, and transplantation was performed in the rats with donor cardiac arrest from 0 to 60, 100, 120, 140, and 160 minutes as lazaroid pretreated groups. The same number of liver transplantations were done in each paired control group without donor lazaroid pretreatment. Recipient survival rates, bile secretion, serum enzymes, and a lidocaine metabolism test were analyzed. RESULTS: Donor lazaroid pretreatment significantly increased recipient 3-day survival rates in groups with 60, 100, and 120 minutes of warm ischemia and 7-day survival with 60 minutes of warm ischemia. Also, the pretreatment increased bile secretion and reduced serum aspartate aminotransferase and lactate dehydrogenase levels in the lazaroid-pretreated groups. CONCLUSIONS: Donor U74006F pretreatment improves viability of livers procured from NHBDs.
AB - BACKGROUND: Lazaroids are potent inhibitors of lipid peroxidation. Whether the compounds can benefit the liver procured from non-heart-beating donors (NHBDs) is unknown. METHODS: Donor rats were pretreated with lazaroid U74006F (4.5 mg/kg) 1 hour before cardiac arrest, and transplantation was performed in the rats with donor cardiac arrest from 0 to 60, 100, 120, 140, and 160 minutes as lazaroid pretreated groups. The same number of liver transplantations were done in each paired control group without donor lazaroid pretreatment. Recipient survival rates, bile secretion, serum enzymes, and a lidocaine metabolism test were analyzed. RESULTS: Donor lazaroid pretreatment significantly increased recipient 3-day survival rates in groups with 60, 100, and 120 minutes of warm ischemia and 7-day survival with 60 minutes of warm ischemia. Also, the pretreatment increased bile secretion and reduced serum aspartate aminotransferase and lactate dehydrogenase levels in the lazaroid-pretreated groups. CONCLUSIONS: Donor U74006F pretreatment improves viability of livers procured from NHBDs.
UR - http://www.scopus.com/inward/record.url?scp=0030032214&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030032214&partnerID=8YFLogxK
U2 - 10.1016/S0002-9610(99)80084-1
DO - 10.1016/S0002-9610(99)80084-1
M3 - Article
C2 - 8554124
AN - SCOPUS:0030032214
SN - 0002-9610
VL - 171
SP - 113
EP - 117
JO - American Journal of Surgery
JF - American Journal of Surgery
IS - 1
ER -